Sprout’s Addyi obtains FDA approval to treat sexual dysfunction in women

Sprout Pharmaceuticals has obtained approval from the US Food and Drug Administration (FDA) for its Addyi (flibanserin 100mg) to treat acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news